Posts

Roche bets $700M upfront on Nurix’s late‑phase BTK degrader to tee up Lilly showdown

Roche is paying Nurix Therapeutics $700 million upfront for rights to bexobrutideg and committing up to $2.3 billion in total potential development, regulatory, and sales milestones. Roche will pay 60% of global development costs and Nurix 40%; the companies will co-develop and co-commercialize bexobrutideg in the U.S., splitting profits and losses 50/50. Outside the U.S., Roche will commercialize the BTK degrader and pay Nurix tiered royalties in the low- to high-teens on ex‑U.S. sales. Bexobrutideg is an investigational oral BTK degrader entering late‑phase testing, with a key Phase 3 trial in chronic lymphocytic leukemia set to initiate this summer and ultimately positioned in a head‑to‑head comparison with Eli Lilly’s Jaypirca. The deal spans B‑cell malignancies, immunology (chronic spontaneous urticaria), and neurology (multiple sclerosis), and the transaction is expected to close in Q3 2026 pending customary conditions, including antitrust clearance. Sources: Roche be...

ADA 2026: Zealand and Roche pitch amylin agonist petrelintide as best‑in‑class obesity monotherapy

Busy FDA gives rare disease sector complementary pathways, unanswered questions – 2026 snapshot

ADA: Metsera asset data support Pfizer’s entry point into obesity market

Roche Launches Up to $2.3B Blood‑Cancer Bet Around Nurix’s BTK Degrader Bexobrutideg

Incyte acquires Vega Therapeutics for up to $2B to add late‑phase bleeding‑disorder asset VGA039

Roche's incretin GLP‑1/GIP shot shows promise in mid‑stage trial for type 1 diabetes

Takeda expects $2.5B hit after Amitiza antitrust verdict, with plans to appeal

AstraZeneca CEO says AI is reshaping drug development and helping boost the odds of success

Otsuka touts new IgAN evidence as it seeks full approval for Voyxact

Innovent declares Phase 3 success for gastric cancer ADC that attracted huge Takeda deal

Lilly and Novo Face Off at ADA 2026 as Others Seek to Compete in Obesity

Lupin Receives U.S. FDA Approval for Ranluspec™ (ranibizumab) Injection: Interchangeable Biosimilar for Eye Diseases Now Cleared in the U.S.